Future Science Group
Browse
FutureOncology_Supplement_v2.0_Resubmission(1).docx (471.16 kB)

Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs - supplementary material

Download (471.16 kB)
dataset
posted on 2023-06-07, 08:51 authored by Mufiza Farid-Kapadia, Madelyn Barton, Zoe Bider-Canfield, Parneet K Cheema, Bishal Gyawali, Natalie M Nightingale, Lidija Latifovic, Henry J Conter

  

Supplementary Table 1: Tumor-Specific Trial Search Strategy

  

Supplementary Table 2: Tumor-Agnostic Trial Search Strategy

  

Exhibit 3: Tumor-agnostic trial characteristics

  

Supplementary Table 4: Tumor-agnostic cohort characteristics

  

Supplementary Table 5: Progression-free survival (PFS) and overall survival (OS) estimates from tumor-agnostic trials.

  

Supplementary Table 6: Tumor-specific trial characteristics

  

Supplementary Table 7: Tumor-specific cohort characteristics

  

Supplementary Table 8. Progression-free survival (PFS) and overall survival (OS) estimates from tumor-specific trials. 

  

Supplementary Figure 1: Meta-analysis of BRAF inhibitors by trial type.

  

Supplementary Figure 2: Meta-analysis of BRAF/MEK inhibitors by trial type.


Funding

Hoffman La Roche, (Grant / Award Number)

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC